Law Offices of Howard G. Smith announces an investigation on behalf of investors of Ironwood Pharmaceuticals, Inc. (“Ironwood” or the “Company”) (NASDAQ: IRWD) concerning the Company and its officers’ possible violations of federal securities laws.

Ironwood is a pharmaceutical company that engages in the research, development and commercialization of human therapeutic products.

On April 26, 2016 Phase Five Research (“Phase Five”) issued a report on the Company entitled “Uncovered: fatal issues linked with Ironwood’s drug, Linzess.” Phase Five claims that while Ironwood has stated that the side effects of Linzess are limited to the gastrointestinal tract, in reality, the “side effects are not limited to the gastrointestinal (GI) tract,” and that the drug is causing “previously unknown, unreported and unlabeled severe systemic adverse events, including documented cases of rapid weight gain, renal failure, seizures and strokes.” Following the release of the Phase Five report, Ironwood shares fell 5.5% on April 26, 2016, thereby injuring investors.

If you purchased Ironwood securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.